Lonza Group - Cutanogen Corporation's Unit Acquisition

Lonza Group - Cutanogen Corporation raised a round of funding on November 18, 2014. Investors include Amarantus Bioscience Holdings.

Cutanogen Corporation is a subsidiary of Lonza which is developing Engineered Skin Substitute (ESS), an autologous skin replacement product for the treatment of Stage 3 and Stage 4 intractable severe …

Articles about Lonza Group - Cutanogen Corporation's Unit Acquisition: